Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies

PURPOSE: Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression (CIM) by protecting hematopoietic stem and progenitor cells and immune system function from chemotherapy-induced damage (myeloprotection). Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussein, Maen, Maglakelidze, Marina, Richards, Donald A, Sabatini, Marielle, Gersten, Todd A, Lerro, Keith, Sinielnikov, Ivan, Spira, Alexander, Pritchett, Yili, Antal, Joyce M, Malik, Rajesh, Beck, J Thaddeus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363477/
https://www.ncbi.nlm.nih.gov/pubmed/34408488
http://dx.doi.org/10.2147/CMAR.S313045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363477/
https://www.ncbi.nlm.nih.gov/pubmed/34408488
http://dx.doi.org/10.2147/CMAR.S313045

Ejemplares similares